Clinigen launches NaviGATE: an educational programme for rare disease patients and organisations 12 September 2023 Clinigen launches NaviGATE: an educational programme for rare diseasepatients and organisations             Accessing hard to reach medicines for people who need them most...

Clinigen divests global rights to four cancer support therapies to CNX Therapeutics 10 August 2023 Clinigen divests global rights to four cancer support therapies to CNX Therapeutics Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, has completed the...

Clinigen initiates a Managed Access Program for relugolix in Europe for the treatment of advanced hormone-sensitive prostate cancer 20 December 2022 Clinigen initiates a Managed Access Program for relugolix in Europe for the treatment of advanced hormone-sensitive prostate cancer Clinigen Limited (‘Clinigen’), the global...